Generic Industry’s Future May Include A Role In The Gene Therapy Space
Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.
You may also be interested in...
AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.
More Than 100 Applications Lost Equivalence Rating Thanks To Allegedly Falsified Data At Two CROs
Sponsors must decide whether to repeat bioequivalence and other studies after two CROs were found to have potentially falsified data, causing the US FDA to reject all data produced by the firms.
GDUFA III Talks Completed
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.